NZ206141A - 5,14-dihydrobenz(5,6)isoindolo(2,1-b)isoquinoline-8,13-dione and pharmaceutical compositions - Google Patents
5,14-dihydrobenz(5,6)isoindolo(2,1-b)isoquinoline-8,13-dione and pharmaceutical compositionsInfo
- Publication number
- NZ206141A NZ206141A NZ206141A NZ20614183A NZ206141A NZ 206141 A NZ206141 A NZ 206141A NZ 206141 A NZ206141 A NZ 206141A NZ 20614183 A NZ20614183 A NZ 20614183A NZ 206141 A NZ206141 A NZ 206141A
- Authority
- NZ
- New Zealand
- Prior art keywords
- compound
- formula
- dimethylformamide
- active ingredient
- solution
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- BFRVNBMAWXNICS-UHFFFAOYSA-N mitoquidone Chemical compound C1=CC=C2C(=O)C3=CN(CC=4C(=CC=CC=4)C4)C4=C3C(=O)C2=C1 BFRVNBMAWXNICS-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 44
- 239000000725 suspension Substances 0.000 claims abstract description 13
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 claims abstract description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 239000002245 particle Substances 0.000 claims description 8
- 239000008215 water for injection Substances 0.000 claims description 7
- 238000007911 parenteral administration Methods 0.000 claims description 6
- 238000000502 dialysis Methods 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008121 dextrose Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000787 lecithin Substances 0.000 claims description 2
- 235000010445 lecithin Nutrition 0.000 claims description 2
- 229940067606 lecithin Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 239000012153 distilled water Substances 0.000 claims 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims 1
- 241001125671 Eretmochelys imbricata Species 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- CMDGQTVYVAKDNA-UHFFFAOYSA-N propane-1,2,3-triol;hydrate Chemical compound O.OCC(O)CO CMDGQTVYVAKDNA-UHFFFAOYSA-N 0.000 claims 1
- 229940083466 soybean lecithin Drugs 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- MHRNGQVWZRPUJI-UHFFFAOYSA-N 2-formyl-3,4-dihydro-1h-isoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CN(C=O)C(C(=O)O)CC2=C1 MHRNGQVWZRPUJI-UHFFFAOYSA-N 0.000 abstract 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 8
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 6
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 229940068968 polysorbate 80 Drugs 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N iso-quinoline Natural products C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- -1 ISOQUINOLINE COMPOUND Chemical class 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229950008882 polysorbate Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8231540 | 1982-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ206141A true NZ206141A (en) | 1986-09-10 |
Family
ID=10534035
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ206141A NZ206141A (en) | 1982-11-04 | 1983-11-03 | 5,14-dihydrobenz(5,6)isoindolo(2,1-b)isoquinoline-8,13-dione and pharmaceutical compositions |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US4831039A (https=) |
| EP (1) | EP0108620B1 (https=) |
| JP (1) | JPS5998084A (https=) |
| KR (1) | KR900008697B1 (https=) |
| AT (1) | ATE25256T1 (https=) |
| AU (1) | AU566898B2 (https=) |
| CA (1) | CA1272198A (https=) |
| DE (1) | DE3369515D1 (https=) |
| DK (1) | DK158666C (https=) |
| ES (1) | ES8504796A1 (https=) |
| FI (1) | FI74003C (https=) |
| GB (1) | GB2129799B (https=) |
| GR (1) | GR78749B (https=) |
| IE (1) | IE56206B1 (https=) |
| IL (1) | IL70124A (https=) |
| NO (1) | NO159933C (https=) |
| NZ (1) | NZ206141A (https=) |
| PH (1) | PH19013A (https=) |
| PT (1) | PT77601B (https=) |
| ZA (1) | ZA838237B (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK158666C (da) * | 1982-11-04 | 1990-11-19 | Glaxo Group Ltd | Analogifremgangsmaade til fremstilling af 5,14-dihydrobenz-oe5,6aa-isoindolooe2,1-baa-isoquinolin-8,13-dion |
| NZ211960A (en) * | 1984-05-03 | 1989-05-29 | Glaxo Group Ltd | Benz(5,6)isoindolo(2,1-b)isoquinoline-8,13-dione derivatives and pharmaceutical compositions |
| GB8513460D0 (en) * | 1985-05-29 | 1985-07-03 | Glaxo Group Ltd | Chemical compounds |
| NO872963L (no) * | 1986-07-29 | 1988-02-01 | Glaxo Group Ltd | Isokinolinderivater. |
| DK616087A (da) * | 1986-11-27 | 1988-05-28 | Glaxo Group Ltd | Isoquinolinderivater og farmaceutiske praeparater indeholdende dem |
| GB8800312D0 (en) * | 1988-01-07 | 1988-02-10 | Glaxo Group Ltd | Process |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4042591A (en) * | 1973-05-30 | 1977-08-16 | Sandoz Ltd. | Naphthoquinone compounds |
| FR2387229A1 (fr) * | 1977-04-13 | 1978-11-10 | Anvar | Dipyrido (4,3-b) (3,4-f) indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
| FR2436786A1 (fr) * | 1978-09-21 | 1980-04-18 | Anvar | Nouveaux derives des pyrido (4,3-b) carbazoles (ellipticines), substitues en position 1 par une chaine polyaminee, leur obtention et leur application a titre de medicaments |
| DK158666C (da) * | 1982-11-04 | 1990-11-19 | Glaxo Group Ltd | Analogifremgangsmaade til fremstilling af 5,14-dihydrobenz-oe5,6aa-isoindolooe2,1-baa-isoquinolin-8,13-dion |
| NZ211960A (en) * | 1984-05-03 | 1989-05-29 | Glaxo Group Ltd | Benz(5,6)isoindolo(2,1-b)isoquinoline-8,13-dione derivatives and pharmaceutical compositions |
-
1983
- 1983-11-01 DK DK499583A patent/DK158666C/da not_active IP Right Cessation
- 1983-11-03 IL IL70124A patent/IL70124A/xx unknown
- 1983-11-03 IE IE2575/83A patent/IE56206B1/xx unknown
- 1983-11-03 CA CA000440383A patent/CA1272198A/en not_active Expired - Fee Related
- 1983-11-03 FI FI834045A patent/FI74003C/fi not_active IP Right Cessation
- 1983-11-03 PT PT77601A patent/PT77601B/pt not_active IP Right Cessation
- 1983-11-03 NZ NZ206141A patent/NZ206141A/en unknown
- 1983-11-03 NO NO834019A patent/NO159933C/no unknown
- 1983-11-03 GB GB08329342A patent/GB2129799B/en not_active Expired
- 1983-11-03 PH PH29787A patent/PH19013A/en unknown
- 1983-11-03 EP EP83306709A patent/EP0108620B1/en not_active Expired
- 1983-11-03 ES ES526995A patent/ES8504796A1/es not_active Expired
- 1983-11-03 DE DE8383306709T patent/DE3369515D1/de not_active Expired
- 1983-11-03 AT AT83306709T patent/ATE25256T1/de not_active IP Right Cessation
- 1983-11-04 AU AU20966/83A patent/AU566898B2/en not_active Ceased
- 1983-11-04 JP JP58207303A patent/JPS5998084A/ja active Granted
- 1983-11-04 GR GR72876A patent/GR78749B/el unknown
- 1983-11-04 ZA ZA838237A patent/ZA838237B/xx unknown
- 1983-11-04 KR KR1019830005234A patent/KR900008697B1/ko not_active Expired
-
1987
- 1987-12-07 US US07/129,064 patent/US4831039A/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69412251T2 (de) | Aromatische nitro verbindungen und deren metabolite verwendbar als anti-virus-und anti-tumormittel | |
| Wall et al. | Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs | |
| CA1259324A (en) | Complexes of flavanolignanes with phospholipids, preparation thereof and associated pharmaceutical compositions | |
| DE69033880T2 (de) | Verfahren zur herstellung von 10,11-Methylendioxy-20(RS)-Camptothecin und 10,11-Methylendioxy-20(S)-Camptothecin-Analog | |
| EP1331005A1 (en) | Medicinal compositions for concominant use as anticancer atent | |
| WO2021121210A1 (zh) | 并环类衍生物、其制备方法及其在医药上的应用 | |
| US8158645B2 (en) | Compound, corresponding compositions, preparation and/or treatment methods | |
| US5036103A (en) | Method of treating cancer cells in humans | |
| WO1986004062A1 (en) | Pharmaceutically active compound and a method for its preparation | |
| CA1272198A (en) | 5,14-dihydrobenz[5,6]isoindolo[2,1-b] isoquinoline-8,13-dione | |
| US4479957A (en) | Use of vindesine in treating acute lymphatic leukemia and _other susceptible neoplasms | |
| CA2484816C (en) | Halo-alkyl esters of camptothecins and methods of treating cancer using these compounds | |
| SK83494A3 (en) | Alkaloides of mappia foetida, method of their production, their use for production of pharmaceutical agents and pharmaceutical agents and pharmaceutical agents containing them | |
| EP0332190A2 (en) | Condensed quinoline system compound, condensed acridine system compound, process for preparing the same, and carcinostatic composition containing the same | |
| JP2724493B2 (ja) | ５−メトキシトリプタミン及びトリプタミン誘導体の合成方法 | |
| JP2003503503A (ja) | 新規のキサントン化合物、その製造および医薬としての使用 | |
| JPH0160471B2 (https=) | ||
| Agrawal et al. | Potential Antitumor Agents III: Sodium Salts of α-[N]-Heterocyclic Carboxaldehyde Thiosemicarbazones | |
| US4002756A (en) | Useful pro-drug forms of theophylline | |
| KR101973456B1 (ko) | 미토콘드리아에 표적화되는 수용성 화합물, 이를 포함하는 조성물 및 이의 제조방법 | |
| KR820000494B1 (ko) | 퀴나졸린 유도체의 제조방법 | |
| Hughes et al. | Metabolism of various 8-aminoquinolines in rhesus monkey. | |
| KR100344099B1 (ko) | 신규한비페닐디카르복실산유도체와이의제조방법 | |
| EP0357092B1 (en) | Preparation of diacetoxybenzylidene diacetates | |
| DE2125588A1 (de) | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |